Medications for the Treatment of Dysthymic Disorder and Double Depression

Exclusion Criteria

• •Other Axis-I diagnoses such as delirium, dementia, and substance dependence (active in last year) or any substance abuse including alcohol within the past six months
• •Actively suicidal
• •CNS neoplasm, demyelinization disease, degenerative neurological disorder, active CNS infection, or any progressive CNS disorder that may confound interpretation of study results
• •History of seizure disorder, or EEG showing paroxysmal activity or head CT showing gross structural abnormality
• •Acute systemic medical disorder
• •Use of any psychotropic medications within 2 weeks prior to screen or 4 weeks prior to screen in the case of fluoxetine
• •Current use of any herbal medication such as St. John's wort,
• •Uncontrolled renal, hepatic, endocrine, cardiovascular, pulmonary, immunological, hematological or gastrointestinal disease
• •Any other abnormal medical screening tests judged by the investigator to be clinically significant
• •Received any experimental medication within 30 days prior to study entry
• •Patients presently in or soon to be starting psychotherapy
• •Prior treatment non-response to an adequate trial of citalopram, escitalopram, or sertraline
• •History of allergy to citalopram, escitalopram or sertraline